NKTR-288 / Nektar Therapeutics - LARVOL DELTA

NKTR-288, a polymer-conjugated interferon gamma mutein for the treatment of solid tumors (SITC 2022) - "Ethics Approval Animal studies were performed under protocols approved by the Institutional Animal Care and Use Committee of Nektar Therapeutics and the Canadian Council on Animal Care. All studies met the ethical and humane criteria for transportation, housing, and care established by the US NIH guidelines or Canadian animal care regulators."

Oncology • Solid Tumor • IFNG • IFNGR1

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (PRNewswire) - "The presentation today showed the sustained pharmacological properties of NKTR-288 relative to native cytokine, including durable exposure and induction of the well characterized interferon gamma response. These data support further evaluation of NKTR-288 as a monotherapy or in combination with checkpoint inhibitors in the clinical setting."

Preclinical • Oncology • Solid Tumor